Importantly, the NLRP3–ASC inflammasome pathway thereby presents as a highly interesting target, concomitantly positively modulating three key pathogenetic features of AD, i.e., Tau pathology, amyloid pathology and neuroinflammation. Here, NLRP3 is linked to amyloidosis.